Genomic Health A.I CyberSecurity Scoring
01/03/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Genomic Health in 2026.
No incidents recorded for Genomic Health in 2026.
No incidents recorded for Genomic Health in 2026.
A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.
CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.
NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement
Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.
Latest updates, reports, and threat intel affecting the global network.
The National Institutes of Health and other agencies tasked with protecting genomic and health data require modern, identity-focused access...
As we wrap up another year and get ready for 2026 to begin, it is once again time for everyone's favorite annual tradition of Health IT...
The life sciences sector sits at the intersection of rapid technological innovation and new opportunities to advance medicine, discover new...
The Advanced Medical Technology Association (AdvaMed) updated its Code of Ethics effective November 1, 2025, primarily to add a new section...
An audit of the National Institutes of Health (NIH) All of Us Research Program has uncovered privacy and security weaknesses that put the...
During the HIMSS Cybersecurity Forum, Dr. Xiaoqian Jiang of the University of Texas Health Science Center at Houston said removing patient...
Privacy and AI counsel Liyue Sigle and Oregon Health & Science University's Monia Reding write the U.S. DOJ's enforcement action against...
The “All of Us” database contains the personal health data of more than 1 million people, including electronic health records and genomic...
TOKYO -- The Japanese government will move to strengthen protections for sensitive personal data, requiring data centers, cloud service...
A security vulnerability has been detected in Sipeed PicoClaw up to 0.2.9. The affected element is the function handleMessageReceive of the file pkg/channels/feishu/feishu_64.go of the component Group Message Handler. Such manipulation leads to missing authorization. The attack can be launched remotely. The exploit has been disclosed publicly and may be used. The reported GitHub issue was closed automatically due to inactivity.
A weakness has been identified in Sipeed PicoClaw up to 0.2.9. Impacted is the function isPrivateOrRestrictedIP of the file pkg/tools/integration/web.go of the component web_fetch. This manipulation causes server-side request forgery. The attack can be initiated remotely. The exploit has been made available to the public and could be used for attacks. Patch name: 2efbe5d560e7ed9bc5209c203dc4aa6ecdbc7405. To fix this issue, it is recommended to deploy a patch.
A security flaw has been discovered in Sipeed PicoClaw up to 0.2.9. This issue affects the function dispatchIncoming of the file pkg/channels/wecom/wecom.go of the component Group Message Handler. The manipulation results in incorrect authorization. It is possible to launch the attack remotely. The exploit has been released to the public and may be used for attacks. The reported GitHub issue was closed automatically due to inactivity.
QueryWeaver contains an authentication bypass vulnerability that allows unauthenticated attackers to obtain valid session tokens for existing accounts by submitting a signup request with a known victim email address. The signup route unconditionally creates and links a new token to the matching Identity via a Cypher MERGE operation before checking whether the email belongs to an existing account, causing the server to return a valid authenticated session token for the victim's identity without requiring any prior credentials or user interaction.
A vulnerability was determined in zhayujie CowAgent up to 2.1.1. This affects the function WebFetch.execute of the file agent/tools/web_fetch/web_fetch.py. Executing a manipulation of the argument url can lead to server-side request forgery. The attack may be performed from remote. The exploit has been publicly disclosed and may be utilized. Upgrading to version 2.1.2 is able to mitigate this issue. This patch is called ea47f3097eed4f8295c4cb3d76ecb97e0f43d632. It is recommended to upgrade the affected component. The vendor was contacted early, responded in a very professional manner and quickly released a fixed version of the affected product.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.